Head-To-Head Survey: Anika Therapeutics (ANIK) & Onconova Therapeutics (ONTX)

Anika Therapeutics (NASDAQ: ANIK) and Onconova Therapeutics (NASDAQ:ONTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Anika Therapeutics and Onconova Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics 0 1 2 0 2.67
Onconova Therapeutics 0 1 3 0 2.75

Anika Therapeutics currently has a consensus target price of $62.50, indicating a potential upside of 16.69%. Onconova Therapeutics has a consensus target price of $8.00, indicating a potential upside of 706.45%. Given Onconova Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Onconova Therapeutics is more favorable than Anika Therapeutics.

Earnings and Valuation

This table compares Anika Therapeutics and Onconova Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics $113.42 million 6.94 $31.81 million $1.96 27.33
Onconova Therapeutics $790,000.00 23.27 -$24.09 million ($2.82) -0.35

Anika Therapeutics has higher revenue and earnings than Onconova Therapeutics. Onconova Therapeutics is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.


This table compares Anika Therapeutics and Onconova Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anika Therapeutics 28.05% 11.91% 11.05%
Onconova Therapeutics -3,061.37% -558.97% -174.38%

Risk & Volatility

Anika Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Onconova Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500.

Insider and Institutional Ownership

84.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Onconova Therapeutics shares are owned by institutional investors. 6.6% of Anika Therapeutics shares are owned by insiders. Comparatively, 13.3% of Onconova Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


Anika Therapeutics beats Onconova Therapeutics on 9 of the 14 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

About Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company’s lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply